Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma

about

Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma

Item

http://www.wikidata.org/entity/Q58573232

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@en

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@nl

type

Item

label

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@en

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@nl

prefLabel

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@en

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@nl

P1476

Serum thymidine kinase 1 is as ...... tients with prostate carcinoma

@en

P2093

Chunmei Wang

http://www.w3.org/2001/XMLSchema#string

Ellen He

http://www.w3.org/2001/XMLSchema#string

Hongbo Ma

http://www.w3.org/2001/XMLSchema#string

Ji Zhou

http://www.w3.org/2001/XMLSchema#string

Jianping Zhou

http://www.w3.org/2001/XMLSchema#string

Junjie Yang

http://www.w3.org/2001/XMLSchema#string

Keqin Zhang

http://www.w3.org/2001/XMLSchema#string

Shujing Li

http://www.w3.org/2001/XMLSchema#string

Sven Skog

http://www.w3.org/2001/XMLSchema#string

Xinling Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Screening for prostate cancer

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Cancer statistics, 2013

Grading of prostatic adenocarcinoma: current state and prognostic implications

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Prostate cancer and inflammation: the evidence.

XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

P304

6171-6180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.9345

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30333882

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6176382

http://www.w3.org/2001/XMLSchema#string